In vitro and in vivo protection against the highly pathogenic H5N1 influenza virus by an antisense phosphorothioate oligonucleotide

Current vaccination strategies and antiviral drugs only provide limited protection against influenza virus infection. In this study, we investigated the use of a novel antisense oligonucleotide (named IV-AS), which is specific for the 5'-terminal conserved sequence found in all eight viral RNA...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antiviral therapy Ročník 13; číslo 1; s. 109
Hlavní autoři: Duan, Ming, Zhou, Zhe, Lin, Ru-Xian, Yang, Jing, Xia, Xian-Zhu, Wang, Sheng-Qi
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 2008
Témata:
Animals
Cell Line
Cytopathogenic Effect, Viral
Dogs
Dose-Response Relationship, Drug
Influenza A Virus, H5N1 Subtype - immunology
Lung - pathology
Lung - virology
Mice
Mice, Inbred BALB C
Oligonucleotides, Antisense - adverse effects
Oligonucleotides, Antisense - immunology
Orthomyxoviridae Infections - immunology
Orthomyxoviridae Infections - virology
Phosphorothioate Oligonucleotides - adverse effects
Phosphorothioate Oligonucleotides - immunology
Specific Pathogen-Free Organisms
Time Factors
ISSN:1359-6535
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Current vaccination strategies and antiviral drugs only provide limited protection against influenza virus infection. In this study, we investigated the use of a novel antisense oligonucleotide (named IV-AS), which is specific for the 5'-terminal conserved sequence found in all eight viral RNA segments of influenza A virus. The activity of IV-AS was monitored both in vitro, in Madin-Darby canine kidney (MDCK) cells, and in vivo using a mouse model. IV-AS was given intranasally to H5N1-infected mice once daily for 6 days starting 6 h after infection. A three-base mismatch of IV-AS was used as a control. IV-AS inhibited influenza virus A induced cytopathic effects in MDCK cells with the 50% effective concentration (EC50) ranging from 2.2 to 4.4 microM. IV-AS was effective against H5N1 virus in preventing death, lessening weight reduction, inhibiting lung consolidation and reducing lung virus titres. Dosages of 40 and 60 mg/kg/day provided 40% and 60% survival rates and prolonged mean survival days in comparison with the infected control group (P<0.05). The lung index in mice treated with IV-AS, at a dose of 20, 40 or 60 mg/kg/day, had been inhibited on day 4 or 6 (P<0.05 or P<0.01); virus titres in lung had declined to 2.42, 1.51 and 1.54 log10 TCID50/g of lung, respectively, whereas the yields in the infected control mice were 6.00 log10 TCID50/g of lung. Our results suggest that the 5'-terminal conserved region of influenza A virus RNA segments can be targeted using antisense technology; therefore, IV-AS is a potential drug for prophylaxis and control of influenza virus infections.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1359-6535
DOI:10.1177/135965350801300112